Bristol-Myers Squibb Company (BMY) Q2 2013 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 1.48%

Bristol Myers Squibb's earnings report shows a slight beat on EPS, which indicates some positive momentum. However, the stock fell by 1.48%, likely due to the lack of revenue details and no updated guidance. Investors may be concerned about the company's future performance without clearer financial expectations.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.44	N/A	+1.15%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautious optimism about future growth despite current market challenges. They emphasized their focus on innovation and product development.

Management highlighted ongoing commitment to innovation.

They acknowledged challenges in the market but expressed confidence in pipeline products.

Bristol Myers Squibb Beats on EPS, Stock Down 1.48%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 1.48%

Key numbers

Management commentary